Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $62.00 | Buy | Canaccord Genuity |
| 9/29/2025 | $60.00 | Buy | TD Cowen |
| 3/13/2025 | $40.00 | Buy | Citigroup |
| 9/13/2024 | $40.00 | Buy | Jefferies |
| 5/3/2024 | $34.00 | Overweight | Wells Fargo |
| 12/29/2021 | $37.00 → $34.00 | Buy | B of A Securities |
– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique p
– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update.
8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
SCHEDULE 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
Canaccord Genuity initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $62.00
TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)
– ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus
LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique p
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 202